The European Medicines Agency (EMA) announced it will review new safety data on the Alzheimer’s disease drug Leqembi (lecanemab). This follows a prior decision to recommend its use in the ...
LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD ...
LEQEMBI is prescribed for Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or in the early dementia stage of the disease, collectively known as early AD, in the U.S. After ...
Biogen and Eisai have won Food and Drug Administration approval of an intravenous maintenance dosing of their Leqembi drug for early Alzheimer's disease. The companies late Sunday said the FDA ...
It’s unknown at this time what net price VHA will be paying for the drug. Leqembi’s annual list price is $26,500. But based on past experience the VHA has been able to extract significant ...
Leqembi is indicated for the treatment of Alzheimer's disease in patients with mild cognitive impairment (MCI) or mild dementia stage of disease in the U.S. (early Alzheimer's disease).
STOCKHOLM, Jan. 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback